Similarly, it was recently shown that HeZD of the essential gene POLR2A, a subunit of RNA polymerase II, creates a therapeutic vulnerability, as cancer cells carrying only a single functional copy of the gene are more sensitive to inhibition of its protein product [3]. The gene discussed is POLR2A; the disease is cancer.